ArticleCancer medicine2019
Trends in intracranial meningioma incidence in the United States, 2004-2015.
Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Health-related quality-of-life outcomes in CNS WHO grade 2 and 3 meningioma: a systematic review.Neurosurgical review · 2025Pooled it
- Risk of intracranial meningioma in patients with acromegaly: a systematic review.Frontiers in endocrinology · 2024Pooled it
- Prevalence of incidental meningiomas and gliomas on MRI: a meta-analysis and meta-regression analysis.Acta neurochirurgica · 2021Pooled it
- Metastases to meningioma-review and meta-analysis.Acta neurochirurgica · 2021Pooled it
- Declining age-adjusted surgical incidence of intracranial meningiomas: a 19-year retrospective analysis from an academic hospital.Journal of neuro-oncology · 2026Article
- Optic nerve sheath meningioma exhibits neural niche-associated transcriptomic features and rare copy number variation-linked evolution.Brain pathology (Zurich, Switzerland) · 2026Article
- Segmenting with confidence through uncertainty quantification for brain tumor imaging.NPJ digital medicine · 2026Article
- Article
- Current landscape of single-cell genomics in meningioma.Neuro-oncology advances · 2026Review
- Diagnostic Value of Routine MRI Parameters in Identifying High-Grade Intracranial Meningiomas.Neuroradiology · 2026Article
- Peritumoral edema in meningiomas: a review of influencing factors, mechanisms, and management.Frontiers in oncology · 2026Review
- Trends in Malignant and Benign Brain Tumor Incidence and Mobile Phone Use in the U.S. (2000-2021): A SEER-Based Study.International journal of environmental research and public health · 2025Article
- Radiation-Induced Meningiomas Have an Aggressive Clinical Course: Genetic Signature Is Limited toJournal of Korean medical science · 2025Article
- Meningioma: Novel Diagnostic and Therapeutic Approaches.Biomedicines · 2025Review
- Survival differences in malignant meningiomas: a latent class analysis using SEER data.Discover oncology · 2025Article
- A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence.Neuro-oncology · 2025Article
- Optimal treatment regimen for very elderly patients with atypical meningioma: an analysis of survival outcomes using the National Cancer Database (NCDB).Journal of neuro-oncology · 2025Article
- Mendelian randomization identifies the characteristic plasma metabolite profile of meningioma.Archives of medical science : AMS · 2025Article
- Radioligand therapies in meningioma: Evidence and future directions.Neuro-oncology · 2024Review
- Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy.Cancer discovery · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMeningioma incidence was reported to have risen substantially in the United States during the first decade of the 21st century. There are few reports about subsequent incidence trends. This study provides updated data to investigate trends in meningioma incidence by demographic and tumor characteristics at diagnosis in the United states from 2004 to 2015.
methodsTrends in meningioma incidence were analyzed using data from the Surveillance, Epidemiology, and End Results-18 (SEER-18) registry database of the National Cancer Institute. The joinpoint program was used to calculate annual percent change (APC) in incidence rates.
resultsThe overall incidence of meningioma increased by 4.6% (95% CI, 3.4-5.9) annually in 2004-2009, but remained stable from 2009 to 2015 (APC, 0; 95% CI, -0.8 to 0.8). Females (10.66 per 100 000 person-years) and blacks (9.52 per 100 000 person-years) had significant predominance in meningioma incidence. Incidence in many subgroups increased significantly up to 2009 and then remained stable until 2015. However, meningioma incidence in young and middle-aged people increased significantly throughout the entire time period from 2004 to 2015 (APC: 3.6% for <20-year-olds; 2.5% for 20-39-year-olds; 1.8% for 40-59-year-olds). The incidence of WHO II meningioma increased during 2011-2015 (APC = 5.4%), while the incidence of WHO III meningioma decreased during 2004-2015 (APC = -5.6%).
conclusionIn this study, the incidence of meningioma was found to be stable in recent years. Possible reasons for this finding include changes in population characteristics, the widespread use of diagnostic techniques, and changes in tumor classification and risk factors in the US population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.